Based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Biomarkers Compendium™ contains information designed to support decision-making around the use of biomarker testing in patients with cancer.
The goal of the NCCN Biomarkers Compendium™ is to provide essential details for those tests which have been approved by NCCN Guideline Panels and are recommended by the NCCN Guidelines®. Tests that measure changes in genes or gene products and which are used for diagnosis, screening, monitoring, surveillance, or for providing predictive or prognostic information are included in the Biomarkers Compendium™. General information on appropriate methodologies for biomarker testing is provided, focusing on the biology or abnormality being measured rather than on commercially available tests or test kits. NCCN anticipates that this compendium may eventually be used by payers in much the same way the NCCN Drugs & Biologics Compendium (NCCN Compendium®) is utilized as a reference for coverage decisions. The NCCN Biomarkers Compendium™ aims to ensure that patients have coverage and access to appropriate biomarker testing based on the evaluations and recommendations of NCCN Panel members.
Clinical professionals should apply independent medical judgment in their decisions about treatment that meets the clinical characteristics and needs of individual patients with cancer. The NCCN Biomarkers Compendium™ is updated in conjunction with the NCCN Guidelines on a continual basis. The listings in the NCCN Biomarkers Compendium™ represent the conclusions of the NCCN Guidelines Panels as of the date of finalization of the relevant NCCN Guideline. The latest NCCN Guidelines and NCCN Biomarkers Compendium™ updates can be accessed at NCCN.org.
For further information on the data included in the NCCN Biomarkers Compendium™, please see:
Acronyms and abbreviations used in the NCCN Biomarkers Compendium™
Types of information included in the NCCN Biomarkers Compendium™
For further information on the use of biomarker testing in oncology, please see:
NCCN Molecular Testing White Paper: Effectiveness, Efficiency, and Reimbursement
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Share Your Feedback
NCCN is interested in working with all constituencies in the cancer care delivery system. We encourage you, as a colleague, to provide input as to how NCCN can enhance the utility and user-friendliness of our information products. Please contact us at email@example.com with your questions, concerns, or comments.
The NCCN Biomarkers Compendium™ is copyrighted by NCCN. All rights reserved. NCCN Content may not be reproduced in any form for any purpose without the express written permission of NCCN. Permissions Requests Section